본문바로가기
Language
Q
U
I
C
K

Leading Innovative Vaccine/Bio Technology SK bioscience

From Prevention To Cure
mouse scroll icon SCROLL DOWN

What’s New

  • SK bioscience News SK bioscience Enters the Third Phas...

    The Korean-developed COVID-19 vaccine?GBP510, is administered to phase 3 clinical trial subj...

    More
  • News SK bioscience’s COVID-19 Vacci...

    Phase I/II stage 1 confirms 5~8 folds of neutraliz...

    More
  • News SK Bioscience Submitted Phase ...

    GBP510 submitted for Phase 3 clinical study in Kor...

    More
  • News SK bioscience reinforces respo...

    ESG Committee will review major management strate...

    More
  • News SK bioscience to Sign MOU with...

    SK invested about 150 billion won in the expansio...

    More

Investor Relations

0 PRESENT PRICE (WON)

0WON

0.00%

Our Products

  • SKY Cellflu prefilled syringe
  • SKY Cellflu Quadrivalent prefilled syringe
  • SKY Zoster Inj.
  • SKY Varicella Inj.
PRODUCTS SKY Cellflu prefilled syringe

The first flu vaccine developed by using the cell-culturing method in Korea. It can provide a large amount of vaccine in a short period of time, as this method can produce a large amount of specific cells which are necessary for cultivating viruses in advance. Furthermore, people with egg allergies can be inoculated at the same time.

SKY Cellflu prefilled syringe image